Impax Laboratories (IPXL +0.3%) announces that it's initiated a Phase IIb trial of IPX159 - a...

|By:, SA News Editor

Impax Laboratories (IPXL +0.3%) announces that it's initiated a Phase IIb trial of IPX159 - a treatment designed to help patients suffering from severe Restless Legs Syndrome.